ProCE Banner Activity

Phase III CROWN: 5-Yr Update of First-line Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC

Conference Coverage

This 5-year update from the phase III CROWN trial reports durable PFS benefit and prolonged time to intracranial progression with first-line lorlatinib vs crizotinib in patients with advanced ALK-positive NSCLC.

Released: June 03, 2024

Expiration: June 02, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.